#DYK our first-in-class antiviral drug-Fc conjugate (DFC) candidate has demonstrated universal activity across #influenza A and B viruses, including potent activity against #H5N1 in preclinical studies? Read more here: bit.ly/3XgCzXA

Our CEO, Jeffrey Stein, spoke with Luke Timmerman on The Long Run podcast about our Cloudbreak platform and novel DFC candidate that has the potential for universal protection against all seasonal and pandemic #influenza A and B strains. Listen here: timmermanreport.com/2024/06/a-long…

We’re pleased to welcome Jim Beitel, MBA to the team as CBO. Jim’s extensive business development, strategy, and operational experience will be invaluable during this pivotal time as we focus exclusively on advancing our Cloudbreak DFC pipeline: cidara.com/news/cidara-th…

We’re pleased to announce the appointment of Rick Bright, Ph.D., Philip Krause, MD, Mario Barro, Ph.D., and Frederick G. Hayden, MD, FACP to our Scientific Advisory Board. Learn more about these #InfectiousDisease experts here: cidara.com/news/cidara-th…

Today we announced the first subjects dosed in our Phase 2b NAVIGATE trial to evaluate the efficacy and safety of our #flu drug-Fc conjugate (DFC) for the pre-exposure prophylaxis of influenza during the current flu season. Read more here: cidara.com/news/cidara-th…

Today we announced two presentations highlighting data on our #influenza drug-Fc conjugate (DFC) candidate at the 2024 OPTIONS XII conference in Brisbane, Australia. Read here for more information on our oral and poster presentations: cidara.com/news/cidara-th…

We’re presenting at this year’s IDWeek! Our two presentations will highlight clinical data on the safety, pharmacokinetics and prophylactic activity of our drug-Fc conjugate (DFC) asset for #influenza. Read more: cidara.com/news/cidara-th… #IDWeek2024

Learn more about our long-acting antiviral drug-Fc conjugate (DFC) for #influenza, and the journey that led to our ongoing Phase 2b clinical trial, in this recent article from BioProcess Online: nam04.safelinks.protection.outlook.com/?url=https%3A%…

Today we announced a $105M private placement led by Venrock Healthcare Capital Partners, with significant participation by new and existing life-sciences focused investors. Read more here: cidara.com/news/cidara-th…

We’re pleased to announce we’ve reached full planned enrollment of 5,000 subjects in our Phase 2b NAVIGATE #ClinicalTrial across sites in the US and UK. Read more about the trial and this important milestone here: cidara.com/news/cidara-th…

Congratulations to our board member, Bonnie L. Bassler, Ph.D., for receiving the National Medal of Science from President Biden for her outstanding contributions to science. We’re proud to have such an incredible scientific leader on our team. Read more: whitehouse.gov/briefing-room/…

We are pleased to announce the appointment of Frank Karbe as Chief Financial Officer. He brings over 25 years of experience as a strategic financial leader, and we look forward to his contributions to the company. Read more about Mr. Karbe here: cidara.com/news/cidara-th…

Our CEO, Jeffrey Stein, Ph.D., was featured in the latest Scrip Asks issue discussing the need for innovative therapies to effectively treat multiple #influenza strains, including those with pandemic potential like #H5N1. Read more: insights.citeline.com/scrip/scrip-as…

Preclinical data assessing our #influenza drug-Fc conjugate (DFC) was published in Nature Microbiology. The paper highlights the potential of our DFC as a potent, universal preventative for influenza A & B in healthy & high-risk populations. Read more: cidara.com/news/cidara-th…

We’re presenting two posters on the potential of our #influenza drug-Fc conjugate at the 38th International Conference on Antiviral Research (#ICAR). Read more about our presentations here: cidara.com/news/cidara-th…

Our CSO, Les Tari, PhD is participating in a panel today at the World Health Organization (WHO) Meeting on Research Important to #H5N1 Influenza Preparedness and Response. See here for more details: cidara.com/news/cidara-th…

#ICYMI our CSO, Les Tari, PhD, recently discussed preclinical results from our Nature Microbiology paper showing universal activity of our DFC against all influenza A & B strains, including strains resistant to other neuraminidase inhibitors. Read more: bit.ly/44dGFD8

We will host a virtual R&D day next Thursday, May 22, from 10-11:30 am ET where key opinion leaders will join company management to discuss our long-acting antiviral drug as a potential universal, once-per-flu season preventative. Read more: cidara.com/news/cidara-th…

We are pleased to announce positive topline results from our Phase 2b NAVIGATE trial evaluating our #influenza drug-Fc conjugate for the prevention of seasonal flu. See here for more information on the results & the link to our conference call today: cidara.com/news/cidara-th…

#ICYMI Cidara was recently featured in an article from Science Magazine highlighting the positive data from our Phase 2b NAVIGATE trial and the promise of our non-vaccine #influenza preventative to offer season-long protection. Read the full story here: bit.ly/40uRzlj